Breast and thyroid cancer: A multicenter study with Accrual to Clinical Trials Network

Merry Peckham, Horace J. Spencer, Shorabuddin Syed, William B. Armstrong, Donald Gregory Farwell, Thomas J. Gal, David Goldenberg, Marika D. Russell, Roberto N. Solis, Deanne King, Brendan C. Stack

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To investigate a possible link between breast and thyroid cancer. Methods: A multicenter retrospective review of patients in the electronic medical records of six Accrual to Clinical Trial (ACT) institutions with both breast cancer and thyroid carcinoma. Each center queried its data using a predefined data dictionary. Information on thyroid and breast cancer included dates of diagnosis, histology, and patient demographics. Results: A random-effects model was used. There were 4.24 million women's records screened, 44 605 with breast cancer and 11 846 with thyroid cancer. The relative risks observed at each institution ranged from 0.49 to 13.47. The combined risk ratio (RR) estimate was 1.77 (95% confidence interval: 0.50–5.18). Conclusion: There was no association between the risk of developing thyroid cancer and being a breast cancer survivor compared to no history of breast cancer, but the range of relative risks among the participating institutions was wide. Our findings warrant further study of more institutions with larger sample size. Additionally, further analysis of the significance of regional RR differences may be enlightening.

Original languageEnglish
Pages (from-to)1211-1217
Number of pages7
JournalJournal of Surgical Oncology
Volume125
Issue number8
DOIs
StatePublished - Jun 15 2022

Bibliographical note

Funding Information:
This study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grants UL1 TR000005 (Accrual to Clinical Trials Network), U54 TR001629 (University of Arkansas for Medical Sciences, UAMS), UL1 TR003107 (UAMS), UL1 TR001414 (University of California, Irvine, UCI), UL1 TR002014 (Pennsylvania State University), UL1 TR001998 (University of Kentucky), UL1 TR001872 (University of California, San Francisco), and UL1 TR001860 (University of California, Davis, UC Davis). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors would like to thank Tyler K. Rose, MD, MS, UAMS; William M. Mitchell, BS, UAMS; Angela Beliveau, UC Davis; and Robynn Zender, MS, UCI.

Funding Information:
This study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grants UL1 TR000005 (Accrual to Clinical Trials Network), U54 TR001629 (University of Arkansas for Medical Sciences, UAMS), UL1 TR003107 (UAMS), UL1 TR001414 (University of California, Irvine, UCI), UL1 TR002014 (Pennsylvania State University), UL1 TR001998 (University of Kentucky), UL1 TR001872 (University of California, San Francisco), and UL1 TR001860 (University of California, Davis, UC Davis). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors would like to thank Tyler K. Rose, MD, MS, UAMS; William M. Mitchell, BS, UAMS; Angela Beliveau, UC Davis; and Robynn Zender, MS, UCI.

Publisher Copyright:
© 2022 Wiley Periodicals LLC.

Keywords

  • breast cancer
  • epidemiology
  • thyroid cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Breast and thyroid cancer: A multicenter study with Accrual to Clinical Trials Network'. Together they form a unique fingerprint.

Cite this